Mechanisms of Imatinib-Reisistance in Gastrointestinal Stromal Tumors (GIST)
نویسندگان
چکیده
منابع مشابه
Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
BACKGROUND Preoperative imatinib mesylate (IM) treatment has not yet been standardized. Here, we aim to further explore such therapy on patients with gastrointestinal stromal tumors (GIST) retrospectively. METHODS Patients experiencing preoperative IM were identified from January 2009 to February 2015. RESULTS A total of 28 GIST patients were identified. The patients received preoperative I...
متن کاملImatinib treatment for gastrointestinal stromal tumour (GIST)
Gastrointestinal stromal tumour (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. GISTs are believed to originate from intersticial cells of Cajal (the pacemaker cells of the gastrointestinal tract) or related stem cells, and are characterized by KIT or platelet-derived growth factor receptor alpha (PDGFRA) activating mutations. The use of imatinib has revolutionized...
متن کاملLaparoscopic Resection of Gastrointestinal Stromal Tumors (gist)
BACKGROUND Gastrointestinal mesenchymal or stromal tumors (GIST) are lesions originated on digestive tract walls, which are treated by surgical resection. Several laparoscopic techniques, from gastrectomies to segmental resections, have been used successfully. AIM Describe a single center experience on laparoscopic GIST resection. METHOD Charts of 15 operated patients were retrospectively r...
متن کاملGastrointestinal Stromal Tumors (GIST) and Their Management.
Gastrointestinal stromal tumor (GIST) is the most common form of sarcoma and can vary in size and clinical outcome from an incidental finding at the time of surgery to life-threatening metastatic disease. Surgery is the standard of care for primary disease, and the oral drug imatinib is the standard of care for metastatic disease. Sunitinib was approved in the United States in early 2006 for GI...
متن کاملGastrointestinal stromal tumors (GIST): new treatment expectations.
Gastrointestinal stromal tumors (GIST) have been known for over twenty years, but until ten years ago they were a heterogeneous group of neoplasms which included leiomyomas, leiomyosarcomas, leiomyoblastomas and schwannomas. They represent approximately 0.5-3 % of all primary tumors of the gastrointestinal tract, only 5 % of visceral sarcomas, but 80 % of malignant tumors originated in the mese...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2012
ISSN: 0923-7534
DOI: 10.1016/s0923-7534(20)32165-7